Log in | Register

Beta-blockers in septic shock to optimize hemodynamics? Yes

Daniel A. Reuter| James A. Russell| Armand Mekontso Dessap
Editorial
Volume 42, Issue 10 / October , 2016

Pages 1607 - 1609

No abstract available.

References

  1. Morelli A, Singer M, Raieri VM, D’Egidio A, Mascia L, Orecchioni A et al (2016) Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. Intensive Care Med. doi:10.1007/s00134-016-4351-2
  2. Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199
    • View reference on publisher's website
    • View reference on PubMed
  3. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
  4. Cecconi M, De Backer D, Antonelli M et al (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40:1795–1815
  5. Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA (2011) Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 39:259–265
    • View reference on publisher's website
    • View reference on PubMed
  6. Wang Z, Wu Q, Nie X, Guo J, Yang C (2015) Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 35:707–716
    • View reference on publisher's website
    • View reference on PubMed
  7. Sanfilippo F, Santonocito C, Morelli A, Foex P (2015) Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin 31:1817–1825
    • View reference on publisher's website
    • View reference on PubMed
  8. Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691
    • View reference on publisher's website
    • View reference on PubMed
  9. Macchia A, Romero M, Comignani PD et al (2012) Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med 40:2768–2772
    • View reference on publisher's website
    • View reference on PubMed
  10. Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, D’Egidio A, Cecchini V, Landoni G, Pietropaoli P, Westphal M, Venditti M, Mebazaa A, Singer M (2013) Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 41:2162–2168
    • View reference on publisher's website
    • View reference on PubMed
  11. Kimmoun A, Louis H, Al Kattani N et al (2015) β1-adrenergic inhibition improves cardiac and vascular function in experimental septic shock. Crit Care Med 43:e332–e340
    • View reference on publisher's website
    • View reference on PubMed
  12. Dimopoulos G, Theodorakopoulou M, Armaganidis A et al (2015) Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa. J Surg Res 198:175–184
    • View reference on publisher's website
    • View reference on PubMed
  13. Ibrahim-Zada I, Rhee P, Gomez CT, Weller J, Friese RS (2014) Inhibition of sepsis-induced inflammatory response by β1-adrenergic antagonists. J Trauma Acute Care Surg 76:320–327
    • View reference on publisher's website
    • View reference on PubMed
  14. Wang Z, Wu Q, Nie X, Guo J, Yang C (2016) Infusion of esmolol attenuates lipopolysaccharide-induced myocardial dysfunction. J Surg Res 200:283–289
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement